Research Analysts Offer Predictions for Ocugen Q2 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for Ocugen in a research note issued on Monday, May 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.06) for the quarter, down from their prior estimate of ($0.05). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Ocugen’s Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at $0.05 EPS, FY2029 earnings at $0.61 EPS and FY2030 earnings at $1.56 EPS.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The firm had revenue of $1.53 million during the quarter, compared to the consensus estimate of $0.42 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 127,987.80%.

Several other equities research analysts have also weighed in on the company. Chardan Capital restated a “buy” rating and issued a $7.00 target price on shares of Ocugen in a report on Wednesday, March 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. Canaccord Genuity Group assumed coverage on shares of Ocugen in a report on Tuesday, March 17th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Oppenheimer started coverage on shares of Ocugen in a report on Wednesday, March 11th. They issued an “outperform” rating and a $10.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $9.75.

Ocugen Stock Down 0.7%

OCGN stock opened at $1.47 on Wednesday. Ocugen has a 1 year low of $0.64 and a 1 year high of $2.73. The company has a fifty day simple moving average of $1.85 and a 200 day simple moving average of $1.58. The company has a current ratio of 1.86, a quick ratio of 1.06 and a debt-to-equity ratio of 4.17. The firm has a market cap of $497.62 million, a PE ratio of -6.13 and a beta of 2.30.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. SmartHarvest Portfolios LLC bought a new stake in Ocugen in the 4th quarter valued at $31,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Ocugen during the 4th quarter worth about $38,000. Verdence Capital Advisors LLC acquired a new position in shares of Ocugen during the third quarter valued at about $47,000. Cora Capital Advisors LLC lifted its stake in shares of Ocugen by 27.5% in the fourth quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock valued at $41,000 after buying an additional 6,500 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Ocugen by 28,222.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company’s stock valued at $41,000 after buying an additional 30,198 shares during the period. 10.27% of the stock is currently owned by institutional investors and hedge funds.

More Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Ocugen will showcase its modifier gene therapy platform at the Retina World Congress and Stifel’s Virtual Ophthalmology Forum, increasing visibility for its pipeline and scientific credibility. Ocugen to Participate in Upcoming May Scientific and Investor Conferences
• Positive Sentiment: The company continues to emphasize its gene-agnostic approach to treating blindness diseases, which could appeal to investors looking for a differentiated biotechnology platform with broad potential applications.
• Neutral Sentiment: Ocugen’s recent earnings update showed revenue ahead of expectations, but the company still posted a quarterly loss, so fundamentals remain mixed.
• Neutral Sentiment: Analyst commentary remains constructive, with HC Wainwright maintaining a Buy rating and a $10 price target, supporting a bullish long-term view despite ongoing losses.
• Negative Sentiment: The press release includes broad forward-looking risk warnings, and there is no new clinical trial data or regulatory approval in this announcement, which may temper enthusiasm about near-term catalysts.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.